HighVista Strategies’s Arcus Biosciences RCUS Stock Holding History

HighVista Strategies’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-71,650	Closed	-$1.48M	–	129
2022 Q4	$1.48M	Hold	71,650	–	–	0.88%	33
2022 Q3	$1.87M	Hold	71,650	–	–	1.07%	30
2022 Q2	$1.82M	Buy	71,650 +21,600	+43%	+$529K	1.1%	29
2022 Q1	$1.58M	Buy	+50,050	New	+$1.68M	1%	27

Other funds holding RCUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

HighVista Strategies's RCUS Position: Q1 2023 in Review

HighVista Strategies sold out of Arcus Biosciences (RCUS) in Q1 2023, closing a stake of 71,650 shares — an estimated $1.48M sold.

HighVista Strategies first reported a position in RCUS in Q1 2022 and held it in 4 quarters. The position peaked at $1.87M in Q3 2022. 179 funds tracked by Wall St. Rank hold RCUS as of Q1 2023.

HighVista Strategies reported no remaining Arcus Biosciences position as of Q1 2023 after selling out during the quarter.
HighVista Strategies sold 71,650 Arcus Biosciences shares in Q1 2023, an estimated $1.48M.
HighVista Strategies first reported a position in Arcus Biosciences in Q1 2022 and held it in 4 quarters.
HighVista Strategies's Arcus Biosciences position peaked at $1.87M in Q3 2022.
179 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2023.

Based on HighVista Strategies's 13F filing for Q1 2023, filed 15 May 2023.